Congratulations to Nir Nimrodi, Chairman and Chief Executive Officer of Accellix on its Series D financing round led by bioMérieux.
Accellix, the Cell Therapy QC company, announced a Series D financing round of $9.5 million led by bioMérieux, a world leader in the field of in-vitro diagnostics for over 55 years. All existing major investors participated in this raise and have also agreed to convert their pre-existing convertible note in the amount of $8.5 million, bringing the company’s total funding in this round to $18 million. This latest round of funding will be used to further expand the market reach of the Accellix system for Cell Therapy QC, enabling its customers greater access to the expertise, scale, resources, and technology needed to effectively assess the quality of life-saving immunotherapies.
Click here to read the full article.
Mark Cohen, Senior Partner and the Chair of the Life Science Practice Group, Darie Ofek, Partner, and Dor Cohen, Associate, in the Corporate Group at our Silicon Beach Office of Pearl Cohen, represented Accellix in the transaction, and represents Accellix in its commercial, corporate and intellectual property matters.
